The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms

被引:4
作者
Aswad, Mohamed Hussam [1 ,2 ]
Kissova, Jarmila [1 ,2 ]
Ovesna, Petra [3 ]
Rihova, Lucie [1 ,2 ]
Penka, Miroslav [1 ,2 ]
机构
[1] Univ Hosp Brno, Dept Clin Hematol, Jihlavska 20, Brno 62500, Czech Republic
[2] Masaryk Univ, Fac Med, Brno, Czech Republic
[3] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno, Czech Republic
来源
IN VIVO | 2021年 / 35卷 / 06期
关键词
Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea; ESSENTIAL THROMBOCYTHEMIA; PROCOAGULANT MICROPARTICLES; RISK-FACTORS; PLATELET; ACTIVATION; SURVIVAL; ARTERIAL; EVENTS;
D O I
10.21873/invivo.12632
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while plateletand erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2(V)(617F) mutation, history of thrombosis, platelets >400 x 10(9)/l, hematocrit >45%, or leukocytes >10x 10(9)/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
引用
收藏
页码:3345 / 3353
页数:9
相关论文
共 43 条
[1]   Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis [J].
Alvarez-Larran, Alberto ;
Arellano-Rodrigo, Eduardo ;
Reverter, Juan Carlos ;
Domingo, Abel ;
Villamor, Neus ;
Colomer, Dolors ;
Cervantes, Francisco .
ANNALS OF HEMATOLOGY, 2008, 87 (04) :269-276
[2]   Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [J].
Alvarez-Larran, Alberto ;
Pereira, Arturo ;
Cervantes, Francisco ;
Arellano-Rodrigo, Eduardo ;
Hernandez-Boluda, Juan-Carlos ;
Ferrer-Marin, Francisca ;
Angona, Anna ;
Gomez, Montse ;
Muina, Begona ;
Guillen, Helga ;
Teruel, Anabel ;
Bellosillo, Beatriz ;
Burgaleta, Carmen ;
Vicente, Vicente ;
Besses, Carles .
BLOOD, 2012, 119 (06) :1363-1369
[3]   Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN [J].
Antonioli, Elisabetta ;
Guglielmelli, Paola ;
Pieri, Lisa ;
Finazzi, MariaChiara ;
Rumi, Elisa ;
Martinelli, Vincenzo ;
Vianelli, Nicola ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
De Stefano, Valerio ;
Za, Tommaso ;
Rossi, Elena ;
Ruggeri, Marco ;
Elli, Elena ;
Cacciola, Rossella ;
Cacciola, Emma ;
Pogliani, Enrico ;
Rodeghiero, Francesco ;
Baccarani, Michele ;
Passamonti, Francesco ;
Finazzi, Guido ;
Rambaldi, Alessandro ;
Bosi, Alberto ;
Cazzola, Mario ;
Barbui, Tiziano ;
Vannucchi, Alessandro M. .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (05) :552-554
[4]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[5]   Molecular biomarkers of thrombosis in myeloproliferative neoplasms [J].
Barbui, Tiziano ;
Falanga, Anna .
THROMBOSIS RESEARCH, 2016, 140 :S71-S75
[6]   Thrombosis in primary myelofibrosis: incidence and risk factors [J].
Barbui, Tiziano ;
Carobbio, Alessandra ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Guglielmelli, Paola ;
Antonioli, Elisabetta ;
Alvarez-Larran, Alberto ;
Rambaldi, Alessandro ;
Finazzi, Guido ;
Barosi, Giovanni .
BLOOD, 2010, 115 (04) :778-782
[7]   Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project [J].
Barosi, Giovanni ;
Mesa, Ruben ;
Finazzi, Guido ;
Harrison, Claire ;
Kiladjian, Jean-Jacques ;
Lengfelder, Eva ;
McMullin, Mary F. ;
Passamonti, Francesco ;
Vannucchi, Alessandro M. ;
Besses, Carlos ;
Gisslinger, Heinz ;
Samuelsson, Jan ;
Verstovsek, Srdan ;
Hoffman, Ronald ;
Pardanani, Animesh ;
Cervantes, Francisco ;
Tefferi, Ayalew ;
Barbui, Tiziano .
BLOOD, 2013, 121 (23) :4778-4781
[8]   Circulating microparticles: square the circle [J].
Barteneva, Natasha S. ;
Fasler-Kan, Elizaveta ;
Bernimoulin, Michael ;
Stern, Joel N. H. ;
Ponomarev, Eugeny D. ;
Duckett, Larry ;
Vorobjev, Ivan A. .
BMC CELL BIOLOGY, 2013, 14
[9]   Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients [J].
Carobbio, Alessandra ;
Thiele, Juergen ;
Passamonti, Francesco ;
Rumi, Elisa ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
Vannucchi, Alessandro M. ;
Antonioli, Elisabetta ;
Gisslinger, Heinz ;
Buxhofer-Ausch, Veronika ;
Finazzi, Guido ;
Gangat, Naseema ;
Tefferi, Ayalew ;
Barbui, Tiziano .
BLOOD, 2011, 117 (22) :5857-5859
[10]   Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients [J].
Cerquozzi, S. ;
Barraco, D. ;
Lasho, T. ;
Finke, C. ;
Hanson, C. A. ;
Ketterling, R. P. ;
Pardanani, A. ;
Gangat, N. ;
Tefferi, A. .
BLOOD CANCER JOURNAL, 2017, 7